224 related articles for article (PubMed ID: 21535941)
1. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
[TBL] [Abstract][Full Text] [Related]
2. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
[TBL] [Abstract][Full Text] [Related]
4. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
Orbach R; Gurevich M; Achiron A
Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
7. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
Brettschneider J; Petzold A; Junker A; Tumani H
Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
[TBL] [Abstract][Full Text] [Related]
8. Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis.
Håkansson I; Gouveia-Figueira S; Ernerudh J; Vrethem M; Ghafouri N; Ghafouri B; Nording M
Prostaglandins Other Lipid Mediat; 2018 Sep; 138():41-47. PubMed ID: 30118859
[TBL] [Abstract][Full Text] [Related]
9. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.
Guimarães I; Cardoso MI; Sá MJ
Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350
[TBL] [Abstract][Full Text] [Related]
10. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
[TBL] [Abstract][Full Text] [Related]
13. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion.
Eisele P; Szabo K; Griebe M; Wolf ME; Hennerici MG; Gass A
Mult Scler; 2014 Sep; 20(10):1391-5. PubMed ID: 24323819
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.
Kroksveen AC; Guldbrandsen A; Vedeler C; Myhr KM; Opsahl JA; Berven FS
Acta Neurol Scand Suppl; 2012; (195):90-6. PubMed ID: 23278663
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
17. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
[TBL] [Abstract][Full Text] [Related]
18. Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis.
Yonar D; Ocek L; Tiftikcioglu BI; Zorlu Y; Severcan F
Sci Rep; 2018 Jan; 8(1):1025. PubMed ID: 29348591
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal synthesis in particular types of multiple sclerosis.
Sladkova V; Mares J; Hlustik P; Langova J; Kanovsky P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):124-6. PubMed ID: 23073520
[TBL] [Abstract][Full Text] [Related]
20. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
